Lexeo Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 3.06 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 251.05M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr...